115 related articles for article (PubMed ID: 7611248)
1. Lipoprotein(a) levels in patients receiving renal replacement therapy: methodologic issues and clinical implications.
Levine DM; Gordon BR
Am J Kidney Dis; 1995 Jul; 26(1):162-9. PubMed ID: 7611248
[TBL] [Abstract][Full Text] [Related]
2. Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients receiving CAPD.
Yang WS; Min WK; Park JS; Kim SB
Am J Kidney Dis; 1997 Oct; 30(4):507-13. PubMed ID: 9328365
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.
Kronenberg F; König P; Neyer U; Auinger M; Pribasnig A; Lang U; Reitinger J; Pinter G; Utermann G; Dieplinger H
J Am Soc Nephrol; 1995 Jul; 6(1):110-20. PubMed ID: 7579063
[TBL] [Abstract][Full Text] [Related]
4. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
Misra M; Webb AT; Reaveley DA; Doherty E; O'Donnell M; Seed M; Brown EA
Adv Perit Dial; 1997; 13():168-73. PubMed ID: 9360675
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients.
Azrolan N; Brown CD; Thomas L; Hayek T; Zhao ZH; Roberts KG; Scheiner C; Friedman EA
Arterioscler Thromb; 1994 Sep; 14(9):1393-8. PubMed ID: 8068598
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease.
Querfeld U; Lang M; Friedrich JB; Kohl B; Fiehn W; Schärer K
Pediatr Res; 1993 Dec; 34(6):772-6. PubMed ID: 8108191
[TBL] [Abstract][Full Text] [Related]
8. Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD.
Kandoussi A; Cachera C; Pagniez D; Dracon M; Fruchart JC; Tacquet A
Kidney Int; 1992 Aug; 42(2):424-5. PubMed ID: 1405325
[TBL] [Abstract][Full Text] [Related]
9. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein (a) levels in end-stage renal failure and renal transplantation.
Barbagallo CM; Averna MR; Sparacino V; Galione A; Caputo F; Scafidi V; Amato S; Mancino C; Cefalù AB; Notarbartolo A
Nephron; 1993; 64(4):560-4. PubMed ID: 8366981
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) in chronic renal disease.
Stenvinkel P; Berglund L
Miner Electrolyte Metab; 1996; 22(1-3):16-21. PubMed ID: 8676811
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation.
Irish AB; Simons LA; Savdie E; Hayes JM; Simons J
Aust N Z J Med; 1992 Jun; 22(3):243-8. PubMed ID: 1386727
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure.
Milionis HJ; Elisaf MS; Tselepis A; Bairaktari E; Karabina SA; Siamopoulos KC
Am J Kidney Dis; 1999 Jun; 33(6):1100-6. PubMed ID: 10352198
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) and treatment of chronic renal disease.
Buggy D; Breathnach A; Keogh B; Cooke T; Feely J
J Intern Med; 1993 Nov; 234(5):453-5. PubMed ID: 8228788
[TBL] [Abstract][Full Text] [Related]
15. Elevated lipoprotein(a) and fibrinogen levels [corrected] increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients.
Bartens W; Nauck M; Schollmeyer P; Wanner C
Perit Dial Int; 1996; 16(1):27-33. PubMed ID: 8616169
[TBL] [Abstract][Full Text] [Related]
16. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J
Ren Fail; 2002 Mar; 24(2):187-95. PubMed ID: 12071592
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease.
Trenkwalder E; Gruber A; König P; Dieplinger H; Kronenberg F
Kidney Int; 1997 Dec; 52(6):1685-92. PubMed ID: 9407518
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.
Gault MH; Longerich LL; Purchase L; Harnett J; Breckenridge C
Nephron; 1995; 70(2):155-70. PubMed ID: 7566298
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.
Irish AB
Metabolism; 1997 Jan; 46(1):36-40. PubMed ID: 9005966
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis.
Thillet J; Faucher C; Issad B; Allouache M; Chapman J; Jacobs C
Am J Kidney Dis; 1993 Jul; 22(1):226-32. PubMed ID: 8322787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
